Journal of Blood Medicine (Mar 2022)
Packed Red Blood Cell Supernatants Do Not Promote Growth or Cisplatin Resistance of Myeloid Leukemia K-562 Cells
Abstract
Kamila Czubak-Prowizor,1,2 Anna Macieja,3 Tomasz Poplawski,4 Halina Malgorzata Zbikowska1 1Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, 90-236, Poland; 2Department of Cytobiology and Proteomics, Medical University of Lodz, Lodz, 92-215, Poland; 3Department of Molecular Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, 90-236, Poland; 4Department of Chemistry and Clinical Biochemistry, Medical University of Lodz, Lodz, 90-136, PolandCorrespondence: Kamila Czubak-Prowizor, Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, Lodz, 90-236, Poland, Tel +48 42 635 44 83, Email [email protected]; [email protected]: A decreased immune surveillance as a consequence of packed red blood cell (PRBC) transfusions has been linked to cancer recurrence and progression, but a causal mechanism remains unclear. During processing and storage of PRBC, numerous bioactive substances accumulate in the acellular fraction (supernatant) of PRBC.Aim: The study aimed to determine whether the supernatant of leukocyte-reduced (LR) and non-leukocyte-reduced (NLR) long-stored PRBC can modulate the survival and proliferation of myeloid leukemia K-562 cells, and the influence of cisplatin (cisPt) on these processes.Methods: Viability, proliferation, DNA damage, intracellular reactive oxygen species (ROS), caspase-3/7 and caspase-9 levels were determined in response to the LR or NLR, fresh (day 1) and long-stored (day 42) PRBCs.Results: The supernatants of fresh (day 1) and stored (day 42) PRBC, in the absence and presence of cisPt, promoted apoptosis of K-562 cells via the increased production of reactive oxygen species (ROS) and increased level of DNA damage, which was manifested by the viability reduction and inhibition of K-562 cell proliferation. No significant influence of the pre-storage leukocyte-filtration and storage time of PRBC units on their anti-proliferative effect was demonstrated.Conclusion: The findings may suggest that the PRBC acellular fraction does not affect chronic myeloid leukemia (CML) progression. However, these issues are pioneering and require further study.Keywords: red blood cell, transfusion, myeloid leukemia, K-562 cells, cisplatin